MicroRNAs as biomarkers for clinical studies

Experimental Biology and Medicine

Volumn 243, Issue 3, 2018, Pages 283-290

  Pogribny, Igor P ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Biomarkers; blood; clinical; diseases; MicroRNA; monitoring

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; NUCLEOTIDE; CIRCULATING MICRORNA;

ADENOCARCINOMA; ARTICLE; BODY FLUID; BREAST CANCER; CANCER DIAGNOSIS; CARDIOVASCULAR DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CIRCULATING TUMOR CELL; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DOWN REGULATION; GENE EXPRESSION; HUMAN; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; SENSITIVITY AND SPECIFICITY; BLOOD; GENETICS; NEOPLASM; PROGNOSIS;

BIOMARKERS; CARDIOVASCULAR DISEASES; CIRCULATING MICRORNA; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS;

EID: 85041707728     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370217731291     Document Type: Article

References (81)

1. FDA-NIH Biomarker Working Group. BEST (biomarkers, endpoints, and other tools) resource, Maryland: Food and Drug Administration (US)/National Institutes of Health (US), 2016.
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843–54.
3. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835–40.
4. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215–33.
5. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CSR, Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672–5.
6. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang C-Y. Characterization microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997–1006.
7. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513–18.
8. American Association for Cancer Research. AACR Cancer Progress Report 2016. Clin Cancer Res 2016; 22: S1–S137.
9. Burkhamer J, Kriebel D, Clapp R. The increasing toll of adolescent cancer incidence in the US. PLoS One 2017; 12: e0172986–e0172986.
10. Weir HK, Anderson RN, Coleman King SM, Soman A, Thompson TD, Hong Y, Moller B, Leadbetter S. Heart disease and cancer deaths – trends and projections in the United States, 1969-2020. Prev Chron Dis 2016; 13: 160211–160211.
11. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524–9.
12. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol 2014; 9: 287–314.
13. Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 2016; 6: 479–91.
14. Wittmann J, Jäck H-M. Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta 2010; 1806: 200–7.
15. Yeh C-H, Moles R, Nicot C. Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer 2016; 15: 37–37.
16. Wang F, Hou J, Jin W, Li J, Yue Y, Jin H, Wang X. Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: a meta-analysis. Molecules 2014; 19: 6282–93.
17. Ferracin M, Lupini L, Salamon I, Saccenti E, Zanzi MV, Rocchi A, Da Ross L, Zagatti B, Musa G, Bassi C, Mangolini A, Cavallesco G, Frassoldati A, Volpano S, Carcoforo P, Hollingsworth AB, Negrini M. Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget 2015; 6: 14545–55.
18. Wang C, Ding M, Xia M, Chen S, Van Le A, Soto-Gil R, Shen Y, Wang N, Wang J, Gu W, Wang X, Zhang Y, Zen K, Chen X, Zhang C, Zhang C-Y. A five-miRNA panel identified from a multicentric case-control study serves as a novel diagnostic tool for ethnically diverse non-small-cell lung cancer patients. EBioMedicine 2015; 2: 1377–85.
19. Lai X, Wang M, McElyea SD, Sherman S, House M, Korc M. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Cancer Lett 2017; 393: 86–93.
20. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 2013; 105: 849–59.
21. Yang X, Guo Y, Du Y, Yang J, Li S, Liu S, Li K, Zhang D. Serum microRNA-21 as a diagnostic marker for lung carcinoma: a systematic review and meta-analysis. PLoS One 2014; 9: e97460–e97460.
22. Li S, Yang X, Yang J, Zhen J, Zhang D. Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis. Clin Exp Med 2016; 16: 29–35.
23. Zhang H-L, Yang L-F, Zhu Y, Yao X-D, Zhang S-L, Dai B, Zhu Y-P, Shen Y-J, Shi G-H, Ye D-W. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011; 71: 326–31.
24. Wang H, Hou L, Li A, Duan Y, Gao H, Song X. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int 2015; 2014: 864894–864894.
25. Tanaka Y, Kamohara H, Kinoshita K, Kurashige J, Ishimoto T, Iwatsuki M, Watanabe M, Baba H. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer 2013; 119: 1159–67.
26. Gao Y, Dai M, Liu H, He W, Lin S, Yuan T, Chen H, Dai S. Diagnostic value of circulating miR-21: an update meta-analysis in various cancers and validation in endometrial cancer. Oncotarget 2016; 7: 68894–908.
27. Lin X-J, Chong Y, Guo Z-W, Xie C, Yang X-J, Zhang Q, Li S-P, Xiong Y, Yuan Y, Min J, Jia W-H, Jie Y, Chen M-S, Chen M-X, Fang J-H, Zeng C, Zhang Y, Guo R-P, Wu Y, Lin G, Zheng L, Zhuang S-M. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicenter, retrospective, longitudinal biomarker identification study with nested case-control study. Lancet Oncol 2015; 16: 804–15.
28. Pan C, Yan X, Li H, Huang L, Yin M, Yang Y, Gao R, Hong L, Ma Y, Shi C, Qin H, Zhang P. Systematic literature review and clinical validation of circulating microRNAs as diagnostic biomarkers for colorectal cancer. Oncotarget 2017 (in press).
29. Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A. Serum miR-200c is a novel prognostic and metatstasis-predictive biomarker in patients with colorectal cancer. Ann Surg 2014; 259: 735–43.
30. Barwari T, Joshi A, Mayr M. MicroRNAs in cardiovascular disease. J Am Coll Cardiol 2016; 68: 2577–84.
31. Cavarretta E, Frati G. MicroRNAs in coronary disease: ready to enter the clinical arena? Biomed Res Int 2016; 2016: 2150763–2150763.
32. Deddens JC, Colijn JM, Oerlemans MIFJ, Pasterkamp G, Chamuleau SA, Doevendans PA, Sluijter JPG. Circulating microRNAs as novel biomarkers for the early diagnosis of acute coronary syndrome. J Cardiovasc Trans Res 2013; 6: 884–98.
33. Navickas R, Gal D, Laucevičius A, Taparauskaitė A, Zdanytė M, Holvoet P. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systemic review. Cardiovasc Res 2016; 111: 322–47.
34. Devaux Y, Mueller M, Haaf P, Goretti E, Twerenbold R, Zangrando J, Vausort M, Reichlin T, Wildi K, Moering B, Wagner DR, Mueller C. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med 2015; 277: 260–71.
35. Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, Kempf T, Wollert KC, Thum T. Dignostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011; 51: 872–5.
36. Jia K, Shi P, Han X, Chen T, Tang H, Wang J. Diagnostic value of miR-30d-5- and miR-125b-5p in acute myocardial infarction. Mol Med Rep 2016; 14: 184–94.
37. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard J-M, Mayr A, Weger S, Schett G, Shah A, Boulanger CM, Willeit J, Chowienczyk PJ, Kiechl S, Mayr M. Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012; 60: 290–9.
38. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263–73.
39. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease–meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.
40. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease–meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.
41. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015; 148: 547–555.
42. Pirola CJ, Fernández-Gianotti T, Castaño GO, Mallardi P, San Marino J, Mora Gonzales Lopez Ledesma M, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015; 64: 800–12.
43. Becker PP, Rau M, Schmitt J, Malsch C, Hammer C, Bantel H, Müllhaupt B, Geier A. Performance of serum microRNAs -122, -192, and -21 as biomarkers in patients with non-alcoholic steatohepatitis. PLoS One 2015; 10: e0142661–e0142661.
44. Liu X-L, Pan Q, Zhang R-N, Shen F, Yan S-Y, Sun C, Xu Z-J, Chen Y-W, Fan J-G. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World J Gastroenterol 2016; 22: 9844–52.
45. Grasso M, Piscopo P, Confaloni A, Denti MA. Circulating miRNAs as biomarkers for neurodegenerative disorders. Molecules 2014; 19: 6891–910.
46. Kumar S, Reddy PH. Are circulating microRNAs peripheral biomarkers for Alzheimer’s disease? Biochim Biophys Acta 2016; 1862: 1617–27.
47. Dong H, Wang C, Lu S, Yu C, Huang L, Feng W, Xu H, Chen X, Zen K, Yan Q, Liu W, Zhang C, Zhang C-Y. A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson’s disease. Biomarkers 2016; 21: 129–37.
48. Correia CN, Nalpas NC, McLoughlin KE, Browne JA, Gordon SV, MacHugh DE, Shaughnessy RG. Circulating miRNAs as potential biomarkers of infectious disease. Front Immunol 2017; 8: 118–118.
49. Villard A, Marchand L, Thivolet C, Rome S. Diagnostic value of cell-free circulating microRNAs for obesity and type 2 diabetes: a meta-analysis. J Mol Biomark Diagn 2015; 6: pii251–pii251.
50. Sebastiani G, Nigi L, Grieco GE, Mancarella F, Ventriglia G, Dotta F. Circulating microRNAs and diabetes mellitus: a novel tool for diseases prediction, diagnosis, and staging? J Edocrinol Invest 2017; 40: 591–610.
51. Brigant B, Metzinger-Le Meuth V, Massy ZA, McKay N, Liabeuf S, Pelletier M, Sallée M, M'Baya-Moutoula E, Paul P, Drueke TB, Burtey S, Metzinger L. Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study. Clin Kidney J 2017; 10: 30–37.
52. Zeng L, Cui J, Wu H, Lu Q. The emerging role of circulating microRNAs as biomarkers in autoimmune diseases. Autoimmunity 2014; 47: 419–29.
53. Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf 2011; 20: 772–7.
54. Marrone AK, Beland FA, Pogribny IP. The role of microRNAs in drug toxicity and in safety assessment. Expert Opin Drug Metab Toxicol 2015; 11: 601–11.
55. Amacher DE, Schomaker SJ, Aubrecht J. Development of blood biomarkers for drug-induced liver injury: an evaluation of their potential for risk assessment and diagnostics. Mol Dign Ther 2013; 17: 343–54.
56. Lee WM. Drug-induced acute liver failure. Clin Liver Dis 2013; 17: 575–86.
57. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009; 106: 4402–7.
58. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DGN, Antoine DJ, French NS, Dhaun N, Webb DJ, Costello EM, Neoptolemos JP, Moggs J, Goldring CE, Park BK. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011; 54: 1767–76.
59. Antoine DJ, Dear JW, Lewis PS, Platt V, Coyle J, Masson M, Thanacoody RH, Gray AJ, Webb DJ, Moggs JG, Bateman DN, Goldring CE, Park BK. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013; 58: 777–87.
60. Vliegenthart ADB, Shaffer JM, Clarke JI, Peeters LEJ, Caporali A, Bateman DN, Wood DM, Dargan PI, Craig DG, Moore JK, Thompson AI, Henderson NC, Webb DJ, Sharkey J, Antoine DJ, Park BK, Bailey MA, Lader E, Simpson KJ, Dear JW. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. Sci Rep 2015; 5: 15501–15501.
61. Harrill AH, Roach J, Fier I, Eaddy JS, Kurtz CL, Antoine DJ, Spencer DM, Kishimoto TK, Pisetsky DS, Park BK, Watkins PB. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther 2012; 92: 214–20.
62. Singhal R, Harrill AH, Menguy-Vacheron F, Jayyosi Z, Benzerdjeb H, Watkins PB. Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine. BMC Pharmacol Toxicol 2014; 15: 42–42.
63. Ward J, Kanchagar C, Veksler-Lublinsky I, Lee RC, McGill MR, Jaeschke H, Curry SC, Ambros VR. Circulating microRNA profiles in human patients with acetaminophen hetatotoxicity or ischemic hepatitis. Proc Natl Acad Sci USA 2014; 111: 12169–74.
64. Krauskopf J, de Kok TM, Schomaker SJ, Gosink M, Burt DA, Chandler P, Warner RL, Johnson KJ, Caiment F, Kleinjans JC, Aubrecht J. Serum microRNA signatures as “liquid biopsies” for interrogating hepatotoxic mechanisms and liver pathogenesis in human. PLoS One 2017; 12: e0177928–e0177928.
65. Lorenzen JM, Kielstein JT, Hafer C, Gupta SK, Kümpers P, Faulhaber-Walter R, Haller H, Fliser D, Thum T. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 2011; 6: 1540–6.
66. Zhao Z, He J, Zhang J, Liu M, Yang S, Li N, Li X. Dysregulated miR1254 and miR579 for cardiotoxicity in patients treated with bevacizumab in colorectal cancer. Tumour Biol 2014; 35: 5227–35.
67. Hur K, Toiyama Y, Schetter AJ, Okugawa Y, Harris CC, Boland CR, Goel A. Identification of a metastasis-specific microRNA signature in human colorectal cancer. J Natl Cancer Inst 2015; 107: dju:492–dju:492.
68. Maierthaler M, Benner A, Hoffmeister M, Surowy H, Jansen L, Knebel P, Chang-Claude J, Brenner H, Burwinkel B. Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. Int J Cancer 2017; 140: 176–87.
69. Kaduthanam S, Gade S, Meister M, Brase JC, Johannes M, Dienemann H, Warth A, Schnabel PA, Herth FJ, Sültmann H, Muley T, Kuner R. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer 2013; 80: 223–7.
70. Selth LA, Towmley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, Goodall GJ, Butler LM, Tilley WD. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 2013; 109: 641–50.
71. Madhavan D, Peng C, Wallwiener M, Zucknick M, Nees J, Schott S, Rudolph A, Riethdorf S, Trumpp A, Pantel K, Sohn C, Chang-Claude J, Schneeweiss A, Burwinkel B. Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. Carcinogenesis 2016; 37: 461–70.
72. Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, Li F, Qi F, Zhang Y, Yang Y, Zhan F, Qiu L. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer 2015; 136: 1835–44.
73. Karakas M, Schulte C, Appelbaum S, Ojeda F, Lackner KJ, Münzel T, Schnabel RB, Blankenberg S, Zeller T. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery diseases-results from large AtheroGene study. Eur Heart J 2017; 38: 516–23.
74. Devaux Y, Vausort M, McCann GP, Kelly D, Collignon O, Ng LL, Wagner DR, Squire IB. A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction. PLoS One 2013; 8: e70644–e70644.
75. Jakob P, Kacprowski T, Briand-Schumacher S, Heg D, Klingenberg R, Stähli BE, Jaguszewski M, Rodondi N, Nanchen D, Räber L, Vogt P, Mach F, Windecker S, Völker U, Matter CM, Lüscher TF, Landmesser U. Profiling and validation of circulating microRnas for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction. Eur Heart J 2017; 38: 511–5.
76. Seronde MF, Vausort M, Gayat E, Goretti E, Ng LL, Squire IB, Vodovar N, Sadoune M, Samuel JL, Thum T, Solal AC, Laribi S, Plaisance P, Wagner DR, Mebazaa A, Devaux Y. GREAT network. Circulating microRNAs and outcome in patients with acute heart failure. PLoS One 2015; 10: e0142237–e0142237.
77. Jarry J, Schadendorf D, Green wood C, Spatz A, van Kempen LC. The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol Oncol 2014; 8: 819–29.
78. Witwer KW. Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin Chem 2015; 61: 56–63.
79. Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int 2015; 2015: 731479–731479.
80. Khan J, Lieberman JA, Lockwood CM. Variability in, variability out: best practice recommendations to standardize pre-analytical variables in the detection of circulating and tissue microRNAs. Clin Chem Lab Med 2017; 55: 608–21.
81. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systematic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010; 15: 673–82.